chlorthalidone / Generic mfg. - LARVOL DELTA

Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. (PubMed, J Clin Hypertens (Greenwich)) - P3 | "Triple combination therapy with Val/Aml/CTD demonstrated superior blood pressure reduction and a favorable safety profile in patients with essential hypertension inadequately controlled on Val/Aml dual therapy, supporting its use as an effective treatment option in this population. Trial Registration: This trial was prospectively registered at ClinicalTrials.gov (identifier: NCT06416865)."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

Strengthening access to antihypertensive medicines through HEARTS in the Americas: the Grenada experience. (PubMed, Rev Panam Salud Publica) - "Grenada adopted a national hypertension clinical pathway specifying a single-pill fixed-dose combination of telmisartan/amlodipine with chlorthalidone as preferred therapy. A standardized clinical pathway can strengthen procurement and promote public-private alignment in hypertension care. Addressing supply chain constraints remains essential for sustained access and continuity of treatment, with lessons applicable to other small island developing states implementing HEARTS."

Journal • Cardiovascular • Hypertension

Racial differences on treatment response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT Trial investigators Background:Racial differences in treatment response to antihypertensive combination therapies remain uncertain.Purpose: To assess whether race modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial was a randomized, double-blind, multicenter study conducted in Brazil, comparing a novel triple single-pill (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) in patients with uncontrolled hypertension. Race does not seem to influence treatment response to single triple-pill combination therapies. The comparative treatment effect of the novel triple single-pill versus active control was consistent across racial groups, with no evidence of effect modification. These findings support the broad applicability of triple single-pill regimens across diverse racial populations."

Cardiovascular • Hypertension

Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT trial investigators Background: Although cardiovascular risk guides initiation of antihypertensive therapy, its influence on the response to single-pill combination regimens remains unclear.Purpose: To assess whether baseline cardiovascular risk modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial compared a novel triple single-pill combination (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) in patients with uncontrolled hypertension. Patients at low/intermediate cardiovascular risk appeared to achieve greater overall SBP reductions than those at high risk. The treatment effect of the novel triple single-pill relative to active control was consistent across cardiovascular risk strata, with no evidence of effect modification. These findings suggest that risk stratification may help..."

Cardiovascular • Hypertension

Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT Trial investigators Background: Further research is needed to better understand sex differences in antihypertensive response to triple single-pill combinations, particularly given the increasing use of these regimens in contemporary clinical practicePurpose: To assess whether sex modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial was a randomised, double-blind, multicenter study conducted in Brazil, comparing a novel triple single-pill combination (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) for patients with uncontrolled hypertension. Women appear to achieve greater response to antihypertensive single-pill combination therapy than men. No difference was observed regarding the treatment effect of the novel triple single-pill combination compared to the active control according..."

Cardiovascular • Hypertension

Comparative Effectiveness of Chlorthalidone Versus Hydrochlorothiazide and Dose-Response of Amiloride on Blood Pressure and Biochemical Parameters. (PubMed, J Am Heart Assoc) - P3 | "Chlorthalidone and hydrochlorothiazide, administered at a 1:2 dosing ratio, show similar effects on BP and laboratory parameters. Amiloride 5 and 10 mg show similar effects on BP and most metabolic parameters, with no clear dose-response relationship, suggesting that any independent BP-lowering effect of amiloride is, at best, weak."

Clinical • HEOR • Journal • Cardiovascular • Hypertension • Hypotension

Pseudomelanosis Duodeni: Endoscopic and Histopathologic Features in an Elderly Male With Comorbid Hypertension, Diabetes, and Chronic Kidney Disease (ACG 2026) - "His medication regimen included chlorthalidone and furosemide, both of which are potentially implicated in the pathogenesis of PD. B.) Esophagastroduodenoscopic image of Forest (III) duodenal ulcer within the duodenal bulb. Figure: Figure 2: (A-B) 20x and 40x image of duodenal bulb biopsy with H&E staining demonstrating multiple black-brown deposits within macrophages in the duodenal sub-epithelium."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Gastroenterology • Hematological Disorders • Hypertension • Melanoma • Metabolic Disorders • Mood Disorders • Nephrology • Peptic Ulcer • Renal Disease • Solid Tumor

CaOx Stone Prevention (clinicaltrials.gov) - P4 | N=80 | Recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Trial completion date: Jun 2027 ➔ Dec 2027 | Trial primary completion date: Jun 2027 ➔ Dec 2027

Trial completion date • Trial primary completion date • Nephrology • Renal Calculi

AQbD-guided development of a robust and green SI-RP-HPLC method for impurity profiling of an efonidipine hydrochloride ethanolate and chlorthalidone combination, with LC-MS and NMR-based identification of degradation product in efonidipine. (PubMed, J Chromatogr A) - "The developed green method exhibited excellent resolution, precision and reproducibility across multiple batches, allowing for effective separation and quantification of impurities. This green QbD-optimized, environmentally sustainable RP-HPLC method provides a reliable and scalable solution for impurity profiling in complex pharmaceutical formulations, aligning with modern quality control and regulatory expectations."

Journal • Cardiovascular • Hypertension

Refractory arterial hypertension: important, but suboptimally characterized. (PubMed, Curr Med Res Opin) - "It is defined as uncontrolled blood pressure on (near-)maximal treatment using ≥ 5 antihypertensive drugs, two of which are long-acting thiazide-like diuretics (e.g. chlorthalidone) and mineralocorticoid receptor antagonists, with an additional requirement in one of the first reports: uncontrolled blood pressure after a minimum of three visits to the department...Some guidelines list treatment for refractory HTN, but the definition of refractory HTN is actually resistant to HTN. Generally, what is recognized as insufficient for the definition of resistant HTN is also likely true for refractory HTN."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Obstructive Sleep Apnea • Pulmonary Arterial Hypertension • Respiratory Diseases • Sleep Disorder

Design-Assisted Chemometric UV Spectrophotometric Determination of Candesartan Cilexetil, Chlorthalidone and Amlodipine Using Principal Component Regression, Partial Least Squares and Genetic Algorithm-Partial Least Squares Models. (PubMed, Anal Sci Adv) - "In addition, the graphical layout tool for analytical chemistry evaluation (GLANCE) visualization framework provided a comprehensive graphical assessment of analytical performance and sustainability metrics. The proposed chemometric strategy offers a rapid, reliable, cost-effective and environmentally friendly alternative for routine quality control of multicomponent pharmaceutical formulations."

Journal • Acute Myelogenous Leukemia

Minimally Symptomatic Severe Hyponatremia: Two Case Reports. (PubMed, Clin Pract Cases Emerg Med) - "Thiazide diuretic use, particularly chlorthalidone, is an important consideration when evaluating patients with new-onset hyponatremia, especially in the setting of excess volume losses or increased consumption of water. These cases demonstrate how patients with severe hyponatremia can present with atypical or mild clinical symptoms and often do not demonstrate significant neurological symptoms such as seizures."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Heart Failure

Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

Which Genes Promote Non-Surgical Biochemical Hypoparathyroidism Beyond Age 70? (ENDO 2026) - "She previously took weekly Fosamax inconsistently and supplements with calcium and vitamin D. She denied fractures, steroid use, kidney stones, family history of osteoporosis, or prior head/neck radiation or surgery...Chlorthalidone 12.5 mg daily was started, with repeat urine calcium planned in four weeks...Activating antibodies to the calcium sensing receptor were considered. This case highlights the incomplete understanding of the genetic basis of hypoparathyroidism, as even comprehensive multi-gene panel testing identifies causative mutations in only 27-35% of patients with non-surgical hypoparathyroidism, suggesting that additional undiscovered genes or regulatory mechanisms likely contribute to this disorder and warrant further investigation through whole exome or whole genome sequencing approaches."

Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Hypertension • Hypoparathyroidism • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Calculi • Type 2 Diabetes Mellitus • CYP24A1 • GATA3 • GNA11 • GNAS • TBX1

Normocalcemic Tertiary Hyperparathyroidism from Chronic Iatrogenic Malabsorption (ENDO 2026) - "Post-transplant immunosuppression (tacrolimus, mycophenolate mofetil, prednisone) and RYGB-related fat-soluble vitamin malabsorption resulted in vitamin D deficiency (undetectable at diagnosis), low vitamin A, phosphorus, urine calcium, and iron deficiency anemia...PTH demonstrated partial but incomplete suppression (111–170 pg/mL; ~60-70% reduction from baseline) during prolonged high-dose calcium repletion (up to 4800 mg/day) and chlorthalidone... This case demonstrates prolonged iatrogenic malabsorption causing severe micronutrient deficiency, SHPT, and biochemical transition to normocalcemic THPT. Calcium challenge literature describes partial suppression of parathyroid hyperplasia (2). Nutritional therapy alone improved BMD despite weight loss."

Endocrine Disorders • Fibrosis • Hematological Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Musculoskeletal Diseases • Osteoporosis • Secondary Hyperparathyroidism

Vancomycin-Associated Acute Tubular Injury Leading to Transient Arginine Vasopressin Resistance (ENDO 2026) - "We present a case of a 66-year-old woman with cerebral palsy, intellectual disability and deep venous thrombosis on apixaban who presented with sepsis...She had urinary retention and gram-positive bacteremia consistent with urosepsis and was started on vancomycin and piperacillin-tazobactam...A desmopressin (IV 2 mcg) trial resulted in only 12% increase in urine osmolality (from 121 to 136 mOsm/kg)...As patient's renal function gradually improved, chlorthalidone was initiated and uptitrated with minimal effect on urine output...Serum copeptin is a valuable biomarker that can help in establishing the diagnosis when conventional testing is indeterminate. Thiazide diuretics alone may be insufficient for management, and indomethacin represents an effective therapeutic option that can improve polyuria by inhibiting renal prostaglandins, which otherwise antagonize AVP signaling in the collecting duct."

Acute Kidney Injury • Cardiovascular • Cerebral Palsy • CNS Disorders • Developmental Disorders • Hematological Disorders • Infectious Disease • Mental Retardation • Metabolic Disorders • Nephrology • Renal Disease • Septic Shock • Thrombosis

LODESTAR: LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: VA Office of Research and Development

New P2 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Retraction: Efficacy & safety of chlorthalidone vs. hydrochlorothiazide in hypertension: A systematic review & meta-analysis. (PubMed, Indian J Med Res) - No abstract available

Journal • Retrospective data • Cardiovascular • Hypertension

Risk of skin cancer from hydrochlorothiazide and other diuretics across races: a global cohort study. (PubMed, Environ Toxicol Pharmacol) - "HCTZ is associated with an increased risk of skin cancers only among whites, while similar associations were not observed in other races. These findings may be considered when prescribing thiazide diuretics in this population."

Journal • Basal Cell Carcinoma • Cardiovascular • Genetic Disorders • Hypertension • Melanoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

TRACKING THIAZIDE THERAPY TREATMENT PATTERNS IN RECURRENT STONE FORMERS USING ON-TREATMENT 24-HOUR URINE ANALYSIS (AUA 2026) - "We included those prescribed a thiazide diuretic (hydrochlorothiazide, chlorthalidone, or indapamide) within 6 months of urine collection and who had a follow-up collection 30–180 days after their first prescription fill. Although underutilized, on-treatment testing provides clinically actionable information in the management of patients with kidney stones. Biochemical response to thiazide therapy influenced prescribing decisions, including continuation, dosage adjustment, and medication class switching. Greater uptake of guideline-recommended on-treatment testing may enhance individualized care for stone formers and optimize the use of preventive pharmacologic therapy."

Nephrology • Renal Calculi

Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association. (PubMed, JACC Case Rep) - "Clinicians should consider monitoring serum sodium in patients receiving GLP-1 receptor agonists, particularly when used alongside medications affecting sodium balance, such as thiazide-like diuretic agents."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity

Graham-Little-Piccardi-Lassueur syndrome and its relation to Antigen mimicry (EADV-Sp 2026) - "These findings were consistent with lichen planus hypertrophicus 2a: cicatricial alopecia HE x 40 2b: Lichen planus hypertrophicus HE x 40 2c: Lichen hypertrophicus HE x 100 Results Initial therapy included loratadine and topical clobetasol propionate. Due to the suspicion of possible drug-induced autoimmunity, the antihypertensive therapy, which consisted of valsartan, bisoprolol, spironolactone, and chlorthalidone, was discontinued and replaced with moxonidine...Prescribed outpatient treatment included acitretin, bilastine, and topical prednisolone for the scalp. Improvement was observed in the lesions located on the trunk and upper and lower extremities following betamethasone/salicylic acid ointment was prescribed, and methylprednisolone aceponate cream...It is this fact that suggests that polymedication could also be considered as a trigger of lichen planus and its subforms such as GLPLS. Conclusions The hypothesis about antigen / molecular mimicry, based on the..."

Alopecia • Dermatopathology • Immunology • Infectious Disease • Lichen Planus • Urology

DIURESED: Diuretic Use in Hemodialysis Patients With Residual Renal Function (clinicaltrials.gov) - P4 | N=2 | Terminated | Sponsor: University of Alberta | N=34 ➔ 2 | Suspended ➔ Terminated; Personnel/staffing issues.

Enrollment change • Trial termination • Chronic Kidney Disease • Nephrology • Renal Disease

Improvement in Resistant Hypertension Following Thymoma Resection: A Case of Paraneoplastic Hypertension (NKF-SCM 2026) - "Prior to surgery, his primary care provider had him on an unusual BP regimen that included sacubitril-valsartan, chlorthalidone, guanfacine, clonidine, and potassium chloride. CONCLUSION This case highlights the importance of thorough evaluation and individualized management in patients with complex resistant hypertension and multiple comorbidities. It also suggests potential effect of thymomas on increasing blood pressure."

Clinical • Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • Cushing’s Disease • Endocrine Disorders • Genetic Disorders • Hematological Disorders • Hypertension • Immunology • Obesity • Obstructive Sleep Apnea • Renal Disease • Respiratory Diseases • Sleep Disorder • Solid Tumor • Thymoma • Thymus Cancer

New-onset hypertension and nephrotic range proteinuria: a rare initial presentation of IgA nephropathy (NKF-SCM 2026) - "He was started on amlodipine, carvedilol, and chlorthalidone with good BP control. Atorvastatin and fish oil were started for dyslipidemia...He was started on sparsentan but discontinued it due to nausea and headaches. He was switched to lisinopril 5 mg daily, and UPCR improved to 0.7 in Nov 2025...In IgAN, proteinuria varies from 3.5 g/day, with nephrotic range proteinuria in <10% of cases. Due to high risk of progression, prompt treatment to reduce proteinuria to <0.5 g/day is indicated to improve long-term outcomes in IgAN."

Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Glomerulonephritis • Hypertension • IgA Nephropathy • Metabolic Disorders • Nephrology • Renal Disease